cate of Mailing or Transmission

I, the undersigned, hereby certify that this correspondence along with other possible ments has been deposited with the U.S. Postal Service by first class mail, postage pre-paid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on March 1, 2007

Date:

Patent 0-06-227/16959/US/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:

Haj-Yehia, Abdullah I. et al.

Serial no.:

10/536,628

Filed:

November 21, 2003

Title:

ACE-INHIBITORS HAVING ANTIOXIDANT AND NO-DONOR ACTIVITY

Examiner:

N/A

Art Unit:

1614

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir/Madam:

Information Disclosure Statement

Applicant submits the enclosed information disclosure statement that is being filed herewith prior to the first office action. Accordingly, it is applicant's opinion that the examiner at the U.S. Patent and Trademark Office should consider these references in determining the patentability of this application.

If Applicant becomes aware of other relevant references that are not cumulative of the submitted references, Applicant will submit them.

Respéctfully submitted

Kevin D. McCarthy Reg. No. 35,278

Roach, Brown, McCarthy & Gruber, P.C. 1620 Liberty Building - 420 Main Street Buffalo, New York 14202

PTO/SB/08B (07-05)

Approved for use through 07/31/2006, OMB 0951-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Substitute	for form 1449/P10			Application Number 10/536,628		
INFORMATION DISCLOSURE				Filing Date	Nov/27/2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	HAJ-YEHIA, Abdullah Ibrahim	
				Art Unit	1614	
(Use as many sheets as necessary)				Examiner Name		
Sheet	4	of	5	Attorney Docket Number	0-06-227	

Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Amery A. et al.: Lancet 1 (1985) 1349-54	
		Ames B.N. et al.: Proc. Natl. Acad. Sci. USA. 90 (1993) 7915-22	
		Opie L. H.: Drugs for the heart, 5th ed. (2001) pp 107-153	
		Garison J.C. et al: Cardiovascular Drugs, In: Goodman and Gillman's: The Pharmacological Basis of Therapeutics, Goodman A.G. et al., 8th ed. Pergamon Press, USA. p. 752 (1990)	
	•	Ondetti M.A.: Circulation 77 (supp I) (1988) I74-I78	
		Griendling, K.K. et al.: Circ. Res. 74 (1994) 1141-48; Rajagopalan, S. et al.: J Clin. Invest. 97 (1996) 1916-23	
		Bartosz M.: Free Radical Biology and Medicine 23 (1997) 729-35; Mak I.T.: Biochem. Pharmacol. 40 (1990) 2169-75	
		Munzel T. J: Clin. Invest. 95 (1995) 187-94	
		Haj-Yehia A. et al.: Drug. Development Res.50 (2000) 528-36	
		Wolf et al., J. Neurosurg. 89 (1998) 279-88	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Initial conformance considered in the citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute for form 1449/PTO	Application Number	10/536,628	
NFORMATION DISCLOSURE	Filing Date	Nov/27/2003	
STATEMENT BY APPLICANT	First Named Inventor	HAJ-YEHAI, Abdula Ibrahim	
###	Art Unit	1614	
(Use as many sheets as necessary)	Examiner Name		

Attorney Docket Number

0-06-227

Sheet

Examiner

5

of

5

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	`	Iwanaga Y. et al., The FASEB Journal, vol. 18, March 2004, pages 587-588	
		Rajagopalan, S. et al.: J Clin. Invest. 97 (1996) 1916-23	
	- *	Zusman, R.M.: Am. J. Cardiol. 72 (1993) 25H-36H	
			·

Considered Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.